ALLOB Shows 90% Fusion Rate at 2 Years in Phase IIa Study

Bone Therapeutics announced positive 24-month follow-up results for the Phase IIa study with ALLOB allogeneic cell therapy in patients undergoing lumbar spinal fusion.

The data show a successful lumbar vertebrae fusion of 90%, with continued clinical improvements in function and pain, from as early as six months after treatment, up to the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us